GT BIOPHARMA, INC. Debt Securities, Available-for-sale, Realized Gain
GT BIOPHARMA, INC. (GTBP) reported Debt Securities, Available-for-sale, Realized Gain of $48.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-21.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGain · last filed 2025-02-21
- GT BIOPHARMA, INC. debt securities, available-for-sale, realized gain for the quarter ending 2023-12-31 was $5.00K.
- GT BIOPHARMA, INC. debt securities, available-for-sale, realized gain for the quarter ending 2023-09-30 was $5.00K.
- GT BIOPHARMA, INC. debt securities, available-for-sale, realized gain for fiscal 2023 was $48.00K.
| Period end | Debt Securities, Available-for-sale, Realized Gain 3 month | Debt Securities, Available-for-sale, Realized Gain 6 month | Debt Securities, Available-for-sale, Realized Gain 9 month | Debt Securities, Available-for-sale, Realized Gain 12 month |
|---|---|---|---|---|
| 2023-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $10.00K derived: sum of 2 quarters · filed 2025-02-21 | $48.00K 10-K · filed 2025-02-21 | |
| 2023-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $43.00K 10-Q · filed 2023-11-01 | ||
| 2023-06-30 | $38.00K 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |